BioLineRx (BLRX) Cash from Financing Activities (2013 - 2026)

BioLineRx's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at -$1.3 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities fell 12.89% year-over-year to -$1.3 million; the TTM figure through Dec 2025 stood at $8.9 million (down 56.99% YoY), while the FY2025 annual figure was $8.9 million, down 56.99% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at -$1.3 million, down from -$916000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $41.9 million in Q1 2021, with the low at -$1.3 million in Q4 2025.
• The 5-year median for Cash from Financing Activities is $62500.0 (2021), against an average of $6.1 million.
• Peak annual rise in Cash from Financing Activities reached 17920.15% in 2024, while the deepest fall reached 1724.49% in 2024.
• BioLineRx's Cash from Financing Activities stood at $174000.0 in 2021, then sank by 471.84% to -$647000.0 in 2022, then soared by 1914.53% to $11.7 million in 2023, then slumped by 109.45% to -$1.1 million in 2024, then retreated by 12.89% to -$1.3 million in 2025.
• Business Quant data shows BLRX's Cash from Financing Activities at -$1.3 million in Q4 2025, -$916000.0 in Q3 2025, and $1.6 million in Q2 2025.